Clinical trial · Interventional
Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer
Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer: A Prospective Phase II Trial (POHIM_EM Trial)
NCT05876130CI-TRIAL-00077917recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| POHIM_EM | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- POHIM_EM
- description
- adjuvant hypofractionated IMRT for endometrial cancer
- interventionNames
- Radiation: POHIM_EM
Primary outcomes (1)
- measure
- 5-year disease-free survival rate
- timeFrame
- 5 years
- description
- disease-free survival rate after the time of surgery
Secondary outcomes (2)
- measure
- acute toxicities
- timeFrame
- 3 months
- description
- acute toxicities within 3 months according to CTCAE v5.0
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed endometrioid type endometrial cancer * completion of hysterectomy and surgical staging * pathologically confirmed FIGO stage III * ECOG performance status 0 or 1 * adjuvant chemotherapy was done or planned Exclusion Criteria: * presence of distant metastasis * previous history of pelvic radiotherapy * severe and unstable medical condition * previous history of other carcinoma except for thyroid cancer, skin cancer, and endometrial cancer
References
Publications (0)
Data not yet available
No reference posted for this study.